Valeant On Stronger Ground As It Readies For Allergan Showdown
This article was originally published in The Pink Sheet Daily
Executive Summary
The Canadian pharma reported a strong third quarter and an improved debt position as it prepares for the December meeting with Allergan shareholders that could result in an ousting of the Botox-maker’s board.